Ivermectin doesn't lower hospitalization or death risk from COVID, study finds
RapidEye/iStock via Getty Images


A placebo-controlled study of nearly 1600 individuals found that the antiparasitic medicine ivermectin does not lower the incidence of hospitalization or death from COVID-19.
The results, published on medRxiv and yet to be peer reviewed, found that ivermectin taken for three days led to a shortening of symptoms of less than one day.

About half of the participants had received at least two COVID vaccine doses.
Researchers noted that subgroup analyses and the data suggest examining ivermectin in a higher dose and for a longer duration.
Ivermectin is not authorized or approved by the U.S. FDA as a COVID treatment.
Authorized or approved COVID treatments include Pfizer's (NYSE:PFE) Paxlovid, Merck's (NYSE:MRK) Lagevrio (molnupiravir), Gilead Sciences' (NASDAQ:GILD) Veklury (remdesivir), Eli Lilly's (NYSE:LLY) bebtelovimab, and AstraZeneca's (AZN) Evusheld.
A study of 3.5K patients published in late March in the New England Journal of Medicine also found that ivermectin didn't lower hospitalization risk.